Subtype distribution of lymphomas in northwestern Iran: a retrospective analysis of 659 cases according to World Health Organization classification

Javad Jalili1, Amir Vahedi2, Amin Danandehmehr3, Parya Aynechi5, Ali Esfahani4, Yousef Roosta6*, Hooman Nateghian7, Amirhosein Ghafoori Asbagh7 and Fateme Hajihoseinlou7

Abstract

Background The distribution of lymphoma subtypes differs strikingly by geographic variations. However, there is limited information on this research in northern Iran. This study aims to evaluate the incidence, subtype, age, sex, and extranodal distribution of lymphomas diagnosed according to the latest WHO classification in a large referral center in northwestern Iran.

Methods In a retrospective study, the medical records of all patients with a diagnosis of lymphoma made between 2018 and 2021 were retrieved from the pathology archive of Imam Reza Medical Center, Tabriz. Lymphoma diagnosis was also made based on the appreciation of morphologic and immunophenotypic features and genetic characteristics in the context of clinical presentation.

Results This study includes a total of 659 patients with lymphoma diagnosed from 2018 to 2021. The number of lymphoma patients were increased each year, with 51 (7.7%), 96 (14.6%), 244 (40.7%), and 268 (40.7%) reported from 2018 to 2021, respectively. 59% of the patients were men. The participants’ mean age was 50.5 ± 19.8 years, while the mean age at diagnosis was 49.3 ± 19.6 years. 2.1% were precursor lymphoid neoplasm, 61.6% were mature B cell neoplasm, 8.8% were mature T cell neoplasm, and 27.5% were Hodgkin lymphoma. The most prevalent subtype of mature B-cell lymphoma was DLBCL (55.1%), followed by SLL (18.7%). Extranodal involvement was seen in 40.5% of all cases.

Conclusion The subtype distribution of lymphomas in northwestern Iran is reported and compared with studies all over the world and inside Iran.

Keywords Lymphoma, Non-hodgkin lymphoma, Lymphoma subtype, Incidence, Iran
Introduction
Lymphoma is a diverse category of hematological malignancies originating from lymphocytes, with a wide range of underlying etiological factors, clinical presentations, histological features, molecular profiles, and treatment options [1]. The incidence of lymphoma also varies geographically, with the greatest rates in North America and Western Europe and much lower rates in East Asia. However, the total incidence of lymphoma is growing in Asian countries [2]. The Middle East and Iran have a greater prevalence of lymphomas than Western countries [3]. Non-Hodgkin lymphoma (NHL) accounts for 3 to 7% of all cancers in various areas of Iran, ranking fifth and eighth in men and women, respectively [4].

Lymphoma is classified into Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). NHL accounts for approximately 90% of lymphoid neoplasms worldwide and is divided into precursor lymphoid neoplasms, mature B cell neoplasms, and mature T/natural killer (NK)-cell neoplasms. Each classification can be further subdivided based on cell differentiation stage, histological appearance, clinical characteristics, immunological phenotypes, and molecular and cytogenetic variations [5, 6]. More than 80 mature lymphoma entities are recognized in the World Health Organization classification of lymphoid neoplasms, which was amended in 2017. Following the principles of lymphoma classification, lymphoma [5, 7], diagnosis is also based on the appreciation of morphologic and immunophenotypic features and genetic characteristics in the context of clinical presentation [5, 7].

Over the last two decades, substantial studies have suggested environmental impacts and significant etiologic diversity among NHL subtypes [8]. Although genetic and ethnic differences, as well as environmental variables such as socioeconomic issues, have been proposed to explain these geographical differences in the incidence rates and distribution of subtypes, the cause of these differences remains largely unexplained [9]. Comparing incidence, subtypes, and other clinical data in different parts of the world may provide new clues for future etiologic investigations and treatments. This study aims to evaluate the incidence, subtype, age, sex, and nodal/extranodal distribution of lymphomas diagnosed according to the latest WHO classification in a large referral center in Northwest Iran from 2018 to 2021.

Methods
In a retrospective study, the medical records of all patients with a diagnosis of lymphoma made between 2018 and 2021 were retrieved from the pathology archive of Imam Reza Medical Center, Tabriz. This center is affiliated with Tabriz University of Medical Sciences, one of the reference centers in the northwestern region of Iran. Patient information, including demographics (age, gender), initial site involvement (nodal or extranodal), date and age at the diagnosis were collected from the submission forms of pathological sampling and medical registering. Inclusion criteria included all lymphoma cases diagnosed by a specialist physician and classified according to the latest WHO classification of Tumors of Haematopoietic and Lymphoid Tissue. Exclusion criteria included lymphatic leukemias involving the brain and peripheral blood, plasma cell neoplasm, and immunodeficiency-related lymphatic disorders. Cases with inadequate information or inconclusive histopathological findings were also excluded. The primary diagnosis was made based on formalin-fixed paraffin sections of three-micron thick slides stained with Hematoxylin and Eosin (H&E), Periodic Acid Schiff (PAS), Giemsa, silver, and chlorella acetate esterase. In cases in which histochemical methods did not yield conclusive results, the diagnosis and the differentiation of Hodgkin's lymphoma and non-Hodgkin's lymphoma, from epithelial, mesenchymal, and myeloproliferative lesions, were made using immunohistochemical staining of paraffin-embedded sections methods with the following markers: CD3, CD4, CD5, CD8, CD10, CD15, CD20 (L26), CD21, CD23, CD30, CD43, CD45(LCA), CD56, CD79, CD99, Anaplastic large cell lymphoma kinase-1(ALK-1), Epithelial Membrane Antigen(EMA), cyclin D1, BCL-2, BCL-6, MuM1, Kappa(K), Lambda (λ), LMP, Ki-67, EBER, TdT. Flow cytometry (on lymph node aspirates or tissue chops), karyotype on fresh tissue (when available), polymerase chain reaction (PCR) for detection of clonality of IgH and/or TCR gene rearrangement, and in situ hybridization for detection of EBV-encoded small RNA (EBER) and diagnostic translocations were performed. The latter was sometimes beneficial in confirming follicular and Burkitt lymphoma and differentiating other high-grade B cell lymphomas from the latter. IBM SPSS Statistics for Windows, version 26 (IBM Corp., Armonk, N.Y., USA) was used for all statistical analyses. We applied the terms of mean (±standard deviation) to describe continuous variables and count (frequency) to describe other nominal variables. All data were obtained with the approval of the ethics committee of Tabriz University of Medical Sciences.

Results
This study includes a total of 659 patients with lymphoma diagnosed from 2018 to 2021. During the study, the number of lymphoma patients were increased each year, with 51 (7.7%), 96 (14.6%), 244 (40.7%), and 268 (40.7%) reported from 2018 to 2021, respectively. As shown in Fig. 1, B-cell lymphoma had the highest incidence rate among all patients diagnosed each year, whereas T-cell
lymphoma had the lowest number of patients diagnosed over the study years.

In the current study, 59% of the patients were men. The participants' mean age was 50.5±19.8 years, while the mean age at diagnosis was 49.3±19.6 years. Extranodal lymphoma is defined as lymphoma that arises outside of the lymph nodes and thymus. When found in bone marrow, it was confined and lacked lymphoma cell periphery. The mediastinum was also considered to be an extranodal site. In our research, around 40% of the patients showed extranodal involvement. Fourteen cases (2.1% of all) were precursor lymphoid neoplasm, 406 cases (61.6% of all) were mature B cell neoplasm, 58 cases (8.8% of all) were mature T cell neoplasm, and 181 cases (27.5% of all) were Hodgkin lymphoma. Four patients (28.5%) of the 14 precursor lymphoid neoplasms were B-lymphoblastic lymphoma, and 10 cases (71.4%) were mature T cell neoplasm, and 181 cases (27.5% of all) were Hodgkin lymphoma. Four patients (28.5%) of the 14 precursor lymphoid neoplasms were B-lymphoblastic lymphoma, and 10 cases (71.4%) were T-lymphoblastic lymphoma. Of the 181 patients diagnosed with Hodgkin lymphoma, 156 (86.1%) were classical type (CHL), and the rest (13.8%) were nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) (Table 1). The most prevalent subtype of mature B-cell lymphoma (55.1%) was diffuse large B cell lymphoma (DLBCL), followed by small lymphocytic lymphoma (SLL) (18.7%), MALTOMA (9.1%), follicular lymphoma (FL) (4.9%), follicular lymphoma (MCL) and Burkitt lymphoma (BL) (3.2%). There were also other less common subtypes, the details of which are provided in Table 1. Among the 58 cases with a diagnosis of mature T-cell neoplasm, the most prevalent subtype was peripheral T cell lymphoma (PTCL) (44.8%), followed by LP (39.6%), anaplastic large cell lymphoma, ALK-negative (ALCL, ALk negative) (5.1%), hepatosplenic T-cell lymphoma (HSTL) and mycosis fungoides (MF) and angioimmunoblastic T cell lymphoma (AITCL), all with the 3.4% incidence rate among the T-cell neoplasms. The male/female ratio was 1.4 in total, 2.5 for immature lymphoid neoplasms, 1.4 for mature B cell neoplasms, 2.0 for mature T cell neoplasms, and 1.2 for Hodgkin lymphomas (Table 1). The highest M/F ratio was seen in PTCL (4.2), BL (3.3), and DLBCL (2), respectively.

Extranodal involvement was 1.8% in precursor lymphoid neoplasms, 74.5% in mature B cell neoplasms, 11.9% in mature T cell neoplasms, and 11.6% in Hodgkin lymphomas. DLBCL, SLL, and MALTOMA were the three most common kinds of mature B cell neoplasm with extranodal involvement, in order of frequency (Tables 1 and 2). LP among mature T cells, and CHL among Hodgkin lymphoma, were the subtypes with the most extranodal involvement. Overall, the three common sites of extranodal involvement were bone marrow (46.8% of extranodal involvement), thoracic region (12.3%), and soft tissue (9.3%) (Table 2). The other sites of extranodal involvement are listed in Table 2.

The age-specific incidence rate of lymphomas is demonstrated in Fig. 2. Patients with precursor lymphoid neoplasms had an average age of 28.91±24.85 years. The fact that this kind of lymphoma was more common at younger ages was noteworthy. TLBL, in particular, had the greatest frequency among children aged 0 to 14 years. The average age of Hodgkin lymphoma patients was 36.92±18.22 years. CHL had a significantly higher
incidence rate among these lymphomas in the age range of 15–34 years. The majority of mature B cell lymphomas were seen in adults with a mean age of 55.63±17.37. However, the prevalence of BL is greatest in children and decreases in adulthood. The average age of T cell lymphoma patients was 56.27±18.14 years, and the majority of this form of lymphoma was found in adults, with the largest incidence of LP and PTCL occurring between the ages of 65–74 and 55–64 years, respectively.

### Discussion

Epidemiologic studies suggest that the distribution of lymphoma subtypes differs strikingly by geographic variations. However, there is limited information on this research in Northern Iran. This report demonstrates the most extensive descriptive study of subtype distribution of lymphomas classified by the WHO criteria in a single institution in Iran.

Recent studies have reported HL frequency among other types of lymphoma to be less than 10% in various regions [10–12]. The latest research on cancer statistics in US HL made up 9.59% of all lymphomas [13]. In our observation, this figure was 27.5%, with all cases being CHL except for two that were NLPHL. With other studies in Iran reporting higher than worldwide average HL frequency among other types of lymphomas (10~40%) [3, 4, 14, 15], it can be said that Iran has one of the highest HL proportions among other lymphomas in the world. Other countries in the regions of Middle East and North Africa, such as Jordan, Iraq, Bahrain, and Lebanon have also reported high percentages of HL, ranging from 24 to 39%, indicating a similar HL distribution pattern.
This difference can be due to Iran's population structure, as children and young adults comprise the majority of Iran's population. In Western countries, HL shows a bimodal age distribution with a peak incidence in the third and sixth decades of life. In contrast, a high incidence in childhood is seen in developing countries. In addition, HL shows a gradual decline in cases with age in this series, consistent with what was seen in China [15, 16, 20, 21].

BCL compromised 61.6% of all lymphomas reported in this study, similar to those reported in MENA countries [17, 18, 22]. However, a greater number was reported in most East Asian countries such as South Korea (72.5%), China (64.4%), Sri Lanka (65.1%), and Thailand (78.3%) [23– 26]. BCL constitutes a large portion of NHL in US (83.5%) and Europe (79.9%) as well [27, 28].

In accordance with the literature, DLBCL is the most common subtype of B-cell lymphomas in Iran, with SLL being the second in this report. However, BL was the second most common subtype in another study investigating southern Iran [4].

Previous studies reported FL as the second most common NHL subtype with slightly varying percentages [29]. However, in several newer studies, SLL/CLL has been reported as the second most common NHL subtype. Al-Hamadani et al. examined the data of about half a million NHL cases registered in the US from 1998 to 2011, and DLBCL (32.5%), CLL/LL (18.6%), and FL (17.1%) were the three most common subtypes in US [27].

Geographical variation in FL distribution has long been recognized. This difference in follicular lymphoma incidence is attributed to different molecular pathways that lead to lymphoma in patients from different regions. There is also the possibility that some cases were diagnosed only after transformation to diffuse large B-cell lymphoma due to a lack of significant symptoms in low-grade lymphomas. This was inferred by the significantly lower incidence of bcl2 gene rearrangements, the hallmark of FL, in Asian compared to western countries. Naresh et al. proposed that the lower rates of FL compared to DLBCL in developing countries may be due to many DLBCLs having progressed from previously undiagnosed FLs, besides the unique regional, genetic, or environmental factors that might have contributed to such progression [18, 19, 30].

One known major risk factor for mature BCL is immune system abnormality. Immune deficient patients have a markedly increased risk of BCL, particularly DLBCL and BL. Some autoimmune diseases such as Sjögren's syndrome or Hashimoto's thyroiditis are also associated with an increased risk of developing BCLs [31, 32].

It is commonly thought that mature T cell neoplasms display higher rates in the Asian continent than in others. Therefore, racial predisposition has been proposed as a risk factor for T/NK lymphomas [33].

The current study and similar reports from some of the surrounding Middle East countries, as well as the western countries, show a low relative proportion of T-cell

### Table 2 Distribution of extranodal sites of lymphomas

| Subtypes          | SLL (CLL) | DLBCL | FL   | LP   | TLBL | MALTOMA | CHL | BL | PTCL | Others | Total (%) |
|-------------------|-----------|-------|------|------|------|---------|-----|----|------|--------|-----------|
| Sites             |           |       |      |      |      |         |     |    |      |        |           |
| Bone              | 2         | 9     |      | 1    | 1    | 2       |     |    |      |        | 15 (5.6)  |
| Nasal and oral cavity and tonsils | 2 | 5 | 1 | 2 | 2 | 2 | 4 | 33 (12.3) |
| Thyroid           | 1         | 1     |      |      |      | 1       |     |    |      |        | 2 (0.7)   |
| Thoracic region   | 2         | 13    | 2    | 1    | 9    | 2       | 4  |    |      |        | 33 (12.3) |
| Soft tissue       | 19        | 1     | 3    | 1    | 1    | 25 (9.3) |    |    |      |        |           |
| Testis            | 1         | 1     |      |      |      | 1       | 1  |    |      |        | 1 (0.3)   |
| GI                | 5         | 1     | 1    |      |      | 7 (2.6)  |    |    |      |        |           |
| Spleen            | 3         | 1     | 1    |      |      | 8 (2.9)  |    |    |      |        |           |
| CNS               | 4         | 1     | 1    |      |      | 4 (1.4)  |    |    |      |        |           |
| Skin              | 1         | 3     |      |      |      | 4 (1.4)  |    |    |      |        |           |
| BM                | 34        | 31    | 8    | 16   | 2    | 11      | 7  | 2  | 3    | 11     | 125 (46.8) |
| Retro peritoneum  | 2         | 2     |      |      |      | 4 (1.4)  |    |    |      |        |           |
| Pancreas          |           |       |      |      |      | 1 (0.3)  |    |    |      |        |           |
| Ovary             | 1         | 1     |      |      |      | 1 (0.3)  |    |    |      |        |           |
| Peripheral blood  | 1         |       | 4    |      |      | 8 (2.9)  |    |    |      |        |           |
| Orbit             | 2         | 2     |      |      |      | 2 (0.7)  |    |    |      |        |           |
| Lung              | 4         | 3     | 3    | 3    | 1    | 11 (4.1) |    |    |      |        |           |
| Liver             | 1         | 1     |      |      |      | 1 (0.3)  |    |    |      |        |           |
| Kidney            | 2         | 3     |      |      |      | 5 (1.8)  |    |    |      |        |           |
| Total (%)         | 49 (18.3) | 101 (37.8) | 9 (3.3) | 19 (7.1) | 3 (1.1) | 20 (7.4) | 29 (10.8) | 4 (1.4) | 9 (3.3) | 24 (8.9) | 267 |

GI: gastrointestinal, CNS: central nervous system, BM: bone marrow
lymphomas. This is in contrast to its high proportion in East Asian countries like Japan, China, and Korea,
constituting 27–30.5% of NHLs. While in our population, T/NK lymphomas were seen in under 10% of patients. Therefore, racial predisposition has been proposed as a risk factor for T/NK lymphomas [34, 35]. Such significant variation in the geographical distribution of T-cell lymphomas has long been recognized and has been attributed to racial predisposition, HTLV-I viral infection, and lower relative incidence of B-cell NHL in the Far East [15].

A previous large multicenter retrospective study confirmed the geographic variations and reported the high frequency of ATL in Japan, AITL and ETCL in Europe, ALCL and ALK-positive in North America, and ENKTCL in Asian countries other than Japan [36].

As for age-specific incidence, two peaks were seen in precursor lymphoma and TCL age distribution; however, the reported frequency of these subtypes are very low, and no robust generalization can be made. No other bimodal distribution was found for other types of lymphomas.

HL exhibits a gradual decrease in cases with age in this study, consistent with what was seen in China. In contrast, a bimodal age curve (a mode at 15–35 years of age and the second mode in elderly) is apparent in North America [21, 24].

In our study, similar to other reports, a male preponderance was seen in most lymphoma subtypes [24, 34, 37]. This difference was more prominent in TCL and precursor lymphoma cases.

In this study, Extranodal involvements were seen in 20.6% of HL cases and 49.3% of NHL cases. Different countries of the world have reported varying frequencies of extranodal lymphoma cases, for example, India (22%), Iraq (48.3%), China (53.5%), and Korea (53.5%) [18, 24, 38, 39]. Diverse definition criteria, ethnic and genetic factors may cause the fluctuating frequency of extranodal lymphomas.

As reported in previous studies, DLBCL is the most common extranodal lymphoma, which is consistent with our results (37.8%) [38, 40]. Additionally, in this study, extranodal NHL most commonly involved bone marrow, whereas the GI tract, Waldeyer’s ring, nose, and sinuses are the common sites in the literature [41, 42]. Geographical differences in Helicobacter pylori incidence also may play a key role in this difference. The fluctuating frequency of extranodal lymphomas may also be caused by genetic and ethnic factors and diverse definition criteria [35].

In nodal involvement, some lymph node sites have shown a disproportionate prevalence of specific lymphoma subtypes. Laurent et al. examined 938 lymphoma cases in France and the most frequent sites were cervical lymph nodes (36.8% of all cases), inguinal lymph nodes (16.4%), axillary lymph nodes (11.9%), and supraclavicular lymph nodes (11%) [43].

The frequency of lymphomas in Iran is rising, and the increasing trend seen in previous studies in Iran and other countries was also seen in our study [44]. Global patterns of non-Hodgkin lymphoma were studied by Miranda et al., and it was reported that most populations experienced stable or barely increasing incidence rates [45]. Singh et al. predicted a 30% increase in HL cases for 2040 reaching 107,000 cases [35].

Considering that the lymphoma cases, including consultation cases, were referred from all North West regions of Iran, the findings may represent the distribution of lymphoma subtypes in Northern Iran.

**Conclusion**

In conclusion, in the current study, the subtype distribution of lymphomas in northern Iran is reported and compared with studies all over the world and inside Iran. HL has a greater share of lymphomas reported in Iran compared to countries outside the MENA region, with the majority of the cases being CHL. A high percentage of extranodal lymphomas are reported, including a relatively high frequency of bone marrow involvement. This disease’s occurrence differs geographically, showing that regional factors may play an essential role in its etiology. Additional research should be done to recognize the effects of these factors on the incidence of lymphomas.

**Acknowledgements**

We thank the staff of the pathology department of Imam Reza hospital who helped us gather the data used for this analysis.

**Authors’ contributions**

JJ designed the study and interpreted the data. JJ, AV, AD, AS, and YR gathered pathologic and clinical data on patients and participated in data analysis. PA and HN drafted the manuscript and participated in data collection. AGH and FH participated in manuscripts draft and designed the figures. All authors read and confirmed the manuscript.

**Funding sources**

This study was not funded by any particular organization, company, etc.

**Data Availability**

(ADM)

The datasets generated during and/or analyzed during the current study are available at [https://data.mendeley.com/datasets/wg28r74x42](https://data.mendeley.com/datasets/wg28r74x42).

**Declarations**

**Conflict of interest**

The authors declare that there is no conflict of interest.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

The protocol of this study was reviewed by the Ethics Committee of Tabriz University of Medical Sciences (IR.TBZMED.REC.1399.1123). The requirement for informed consent was exempted by the ethics review board of Tabriz Medical University of Medical Sciences. The data is anonymized and no information regarding patients’ identities were disclosed, and therefore,
References

21. Nakatsuka SI, Aozasa K. Epidemiology and pathologic features of Hodgkin lymphomas in Iran. Arch Iran Med. 2007;10(3):345–8.
22. Monabati A, Safaei A, Noori S, Mokhtari M, Vahedi A. Subtype distribution of lymphomas in South of Iran, analysis of 1085 cases based on World Health Organization classification. Ann Hematol. 2016;95(4):613–8.
23. Svensson T, Schou M, Pileri SA, Ley B, Siemensen H, Green R, et al. The epidemiology of lymphoma in Jordan: a nationwide population study. Ann Hematol. 2016 Oct;95(10):1387–98.
24. Aladily TN, Khreisat W, Ashukhaibi O, Alkhatib SM, Annab H, Tarawneh MS, et al. The epidemiology of lymphoma in Bahrain: A retrospective analysis according to the World Health Organization classification. Hematol Oncol Stem Cell Ther. 2021 Dec;14(4):336–42.
25. Nair R, Arora N, Mallath MK. Epidemiology of Non-Hodgkin’s Lymphoma in Guilan Province, Iran. Asian Pac J Cancer Prev. 2016;17:1–4.
26. Al‑Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. The epidemiology of lymphoma in South of Iran, analysis of 1085 cases based on World Health Organization classification. Ann Hematol. 2016;95(4):613–8.
27. Armitage JO, Gascoyne RD, Lunnan MA, Cavalli F. Non-Hodgkin lymphoma. Lancet (London, England). 2017 Jul 15;390(10):299–310.
28. Hashemi-Bahremani M, Parvarech MR, Tabrizchi H, Gupta RK, Rafii MR. Lymphomas in Iran. Arch Iran Med. 2007;10(3):345–8.
29. Monabati A, Safaei A, Noori S, Mokhtari M, Vahedi A. Subtype distribution of lymphomas in South of Iran, analysis of 1085 cases based on World Health Organization classification. Ann Hematol. 2016;95(4):613–8.
30. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein HTJ. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO, 2017. 596 p.
31. Swerdlow SH, Campo E, Pileri SA, Lee Harris N, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 12;127(19):2375–90.
32. De Leval L, Jaffe ES. Lymphoma Classification. Cancer J. 2020 May;26(3):176–85.
33. Chiu BCH, Hou N. Epidemiology and etiology of non-Hodgkin lymphoma. Cancer Treat Res. 2015;165.
34. Muller AW, Horst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol. 2005 Jan;84(1):1–12.
35. Nair R, Arora N, Mallath MK. Epidemiology of Non-Hodgkin’s Lymphoma in India. Ann Hematol. 2016 Mar;95(4):613–8.
36. Vose JM, Neumann M, Harris ME. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30.
37. Bray F, Ferlay J, Soerjomataram I. Cancer incidence in five continents in 2018. Cancer Epidemiol. 2020;65:174–82.
38. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. Cancer J Clin. 2005;55(5):74–95.
39. Shin HR, Oh KW, Kim YG, Park YH, Kim HD, Cho WH, et al. The epidemiology of lymphoma in South Korea: analysis of 5318 cases performed in accordance with the Helsinki Declaration. Ann Oncol. 2010;21(2):224–30.
40. Ehteshami A, Akbari ME, Mokhtari S, Atarbashi Moghadam S. Oral Lymphoma in Iran: A Retrospective Study. Asian Pac J Cancer Prev. 2012;13(10):4889–95.
41. Basirat M, Rabiei M, Bashardoustand N. Incidence of head and neck Lymphomas in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification. Ann Oncol. 2000;11(SUPPL. 1).
42. Fragioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use. Medicine (Baltimore). 2016 Jul;95(25).
43. Chen YK, Lin CL, Cheng FTR, Sung FC, Kao OH. Cancer risk in patients with Hashimoto’s thyroiditis: a nationwide cohort study. Br J Cancer. 2013 Oct;109(9):2496.
44. Akbari ME, Bastani Z, Mokhtari S, Atarbashi Moghadam S. Oral Lymphoma in Iran: A Retrospective Study. Asian Pac J Cancer Prev. 2012;13(10):4889–95.
45. Miranda-Filho A, Piñeros M, Znaor A, Marcos-Gragera R, Steliarova-Foucher E, Bray F. Global patterns and trends in the incidence of non-Hodgkin lymphoma among people aged 50–79 years: A global analysis of 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.